Anondita Medicare, the manufacturer of the popular ‘Cobra’ brand of flavored male condoms, made a powerful debut on the stock market today. The company’s IPO, which had already seen record demand, rewarded investors with almost double returns on listing day.
Strong Market Debut
The shares were issued at ₹145 per piece and got listed on the NSE SME platform at ₹275.50, giving investors a 90% listing gain. The rally didn’t stop there-the stock surged further to ₹288, pushing investors’ profits close to 98.62% on day one.
IPO Subscription Numbers
Anondita Medicare’s ₹69.50 crore IPO was open for subscription between August 22-26 and witnessed a massive response across all categories.
- Overall Subscription: 300.89 times
- QIBs (Qualified Institutional Buyers): 153.03 times (ex-anchor)
- NIIs (Non-Institutional Investors): 531.82 times
- Retail Investors: 286.20 times
The IPO comprised only fresh equity issuance of 47.93 lakh shares with a face value of ₹10 each.
Utilization of Funds
The company has earmarked the IPO proceeds for the following purposes:
| Purpose | Allocation |
|---|---|
| Equipment & Machinery Purchase | ₹6 crore |
| Working Capital Requirements | ₹35 crore |
| Acquisitions & General Corporate Purposes | Remaining funds |
About Anondita Medicare
Founded in March 2024, Anondita Medicare is engaged in the production of flavored male condoms under the Cobra brand. In Noida, Uttar Pradesh, the company has a state-of-the-art production facility that can produce 562 million condoms annually.
Its goods are exported to South-East Asia, Africa, and the Middle East in addition to being sold throughout India. The business collaborates closely on family planning and public health initiatives with governments, non-governmental groups, and international health organizations.
Financial Performance
Anondita Medicare has demonstrated rapid financial growth over the past few years:
- FY2023: Net profit of ₹3.5 crore
- FY2024: Net profit rose to ₹3.84 crore
- FY2025: Net profit surged to ₹16.42 crore
- Revenue Growth: Total income grew at a CAGR of 46%, reaching ₹77.13 crore in FY2025
At the same time, the company’s debt has gradually increased:
- FY2023: ₹22.66 crore
- FY2024: ₹24.01 crore
- FY2025: ₹27.39 crore
Market Outlook
Despite rising debt, Anondita Medicare’s strong revenue growth, expanding global presence, and association with the well-known Cobra brand place it in a promising position. The IPO’s nearly 99% listing gain reflects robust investor confidence in the company’s growth story.
